The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes

Sangeetha Mathavan, Nigel Chen-Tan, Frank Arfuso, Hani Al-Salami

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)


Gliclazide (G) is used to treat type 2 diabetes (T2D), and also has anti-platelet, anti-radical, and anti-inflammatory effects. G has poor water solubility and high inter-individual variations in absorption, limiting its application in type 1 diabetes (T1D). The bile acid, chenodeoxycholic acid (CDCA), has permeation-enhancing effects. Sodium alginate (SA) was used to microencapsulate G and CDCA to produce control (G-SA) and test (G-CDCA-SA) microcapsules. Both microcapsules showed uniform structure, morphology, and good stability profiles. CDCA reduced G-release at pH 7.8, while G-release was negligible at lower pH values in both microcapsules. CDCA incorporation resulted in less swelling and stronger microcapsules, suggesting improved stability.

Original languageEnglish
Pages (from-to)1508-1519
Number of pages12
JournalArtificial Cells, Nanomedicine and Biotechnology
Issue number6
Publication statusPublished - 17 Aug 2016
Externally publishedYes

Cite this